García C, et al. - A novel three-dimensional formulation (Endoret-Gel) based on plasma rich in growth factor technology (Endoret-PRGF) for atrophic scar management was evaluated in the present study. Microstructure analysis, growth factor content, and projection capacity of both formulations (Endoret-Gel and Endoret-PRGF) has been evaluated. In addition, in the case of an extense atrophic scar, a clinical evaluation of Endoret-Gel treatment was also conducted. Endoret-Gel had plasma proteins of high molecular weight that formed solid thermal aggregates surrounded by a stable network of fibrin. Compared with Endoret-PRGF, this formulation has a higher cutaneous projection capacity. Both formulations provided a high load of bioactive proteins in liquid Endoret-PRGF like EGF, PDGF-AB and IGF-I. Such preliminary findings indicate that Endoret-Gel may not only serve as a temporary volumizer but also as a stimulator for soft tissue that could be used as a scar management monotherapy. No side effects or adverse events during the ten-month follow-up period are recorded.